What Does Estrogen Do in the Body? New Research on 10 Systems

Most women were taught that estrogen runs the menstrual cycle and causes hot flashes when it leaves. That's a small piece of the picture.

Estrogen receptors sit on cells in nearly every tissue you have. Your brain, artery walls, liver, muscle, cartilage, gut lining, immune cells, and bladder all respond to it. When estrogen drops in perimenopause, all of those systems feel it, not just your ovaries.

What's changed in the last two years is that researchers can finally measure some of this directly. We now have brain scans that show estrogen receptors in living women, large gut studies that track how bacteria recycle estrogen, and a new medical term for menopause-related joint and muscle pain. In November 2025, the FDA also removed most of the black box warning that kept many women away from hormone therapy for over two decades.

Here is what the newest research shows, system by system.

1. Your brain: it makes more estrogen receptors as estrogen falls

For years the assumption was that the brain simply stops caring about estrogen after menopause. A 2024 study from Weill Cornell showed the opposite.

Researchers used PET scans with a tracer that binds to estrogen receptors to look inside the brains of 54 healthy women aged 40 to 65. Receptor density rose steadily across the menopause transition. Perimenopausal women were in the middle, and postmenopausal women had the highest levels, still elevated into the mid-60s. This was the first time estrogen receptors had been imaged in the living brain outside of breast cancer research.

The researchers read this as the brain compensating. As estrogen drops, brain cells put out more receptors to catch whatever estrogen is left. The changes were independent of age and blood estradiol levels, and receptor density alone correctly sorted every woman into premenopausal or postmenopausal.

Here's the part that matters clinically. Higher receptor density in key regions was linked to poorer memory scores and predicted mood and cognitive symptoms after menopause. In other words, the brain fog and mood shifts many women describe have a measurable signature. The lead researcher has also suggested the "window of opportunity" for estrogen therapy may be longer than once believed, though that still needs to be tested.

Why brain fog happens: the astrocyte connection

At UCLA, Dr. Rhonda Voskuhl's group has been working out the mechanism. In a 2023 study in midlife female mice, losing ovarian hormones caused memory problems and shrinkage in the hippocampus, the brain's learning and memory center. That happened in midlife mice, not young ones, so both aging and estrogen loss were needed.

The key player turned out to be estrogen receptor beta (ERβ) in astrocytes, the support cells that keep neurons fed and connected. Deleting that one receptor in astrocytes caused the same damage as losing all ovarian hormones.

A new estriol finding (September 2026)

That work led to a small study published September 1, 2026 in Scientific Reports. Twenty menopausal women, average age 53, took a combination of estriol and progesterone for 12 months. Estriol is a gentler estrogen that binds mainly to ERβ rather than ERα. By month 12, the women reported significant improvements in brain fog, concentration, working memory, processing speed, verbal memory, and problem solving.

This was a case series with no placebo group, and one author holds patents on the treatment. So it's a signal, not proof. Estriol is also not FDA-approved in the United States. But it's one of the first studies to target menopausal brain fog directly, and it fits the receptor research above.

2. Hot flashes: not just uncomfortable, possibly a warning sign

Hot flashes have long been treated as a nuisance to wait out. Dr. Rebecca Thurston's research at the University of Pittsburgh suggests they may say something about your blood vessels.

Using data from SWAN, the long-running Study of Women's Health Across the Nation, her team found that women with more frequent hot flashes at the start of the study had about double the later risk of heart attack, stroke, and heart failure.

Her brain imaging work points the same way. In a study published in Neurology in January 2023, hot flashes, especially those during sleep, were linked to more white matter hyperintensities. These are small bright spots on MRI that reflect disease in the brain's tiny blood vessels. An earlier pilot found that women had about eight hot flashes a day on a monitor but only reported three, because many happened while they slept. Only the monitor-measured night flashes tracked with brain changes.

Thurston describes hot flashes as a possible midlife marker of heart and brain health. It isn't yet known whether treating them lowers that risk. But frequent night sweats are a good reason to look harder at blood pressure, cholesterol, blood sugar, and sleep.

3. Heart and blood vessels: estrogen keeps arteries relaxed

Women's heart disease risk climbs after menopause, and research presented at the American College of Cardiology in 2025 found it often catches up to that of men of similar age and health.

Part of the reason is how estrogen acts on blood vessels. It helps keep them flexible and relaxed, and it shifts cholesterol toward a healthier pattern. When estrogen falls, arteries tend to stiffen, blood pressure rises, LDL goes up, and HDL comes down.

A recent study in Mathematical Biosciences built a computer model of a woman's kidneys and cardiovascular system to test which of estrogen's many effects matters most for blood pressure. The answer was vasodilation, estrogen's ability to widen and relax blood vessels.

Timing matters

The ELITE trial, published in the New England Journal of Medicine in 2016, followed almost 650 postmenopausal women. Artery walls thickened more slowly on estradiol, but only in women who started within six years of menopause. Women who started later didn't get that benefit.

The researchers' explanation: estrogen helps healthy vessels stay healthy, but it can't undo damage that's already there. This is the basis of the "timing hypothesis," and it's why the conversation about hormones belongs in perimenopause, not ten years later.

Route may matter too. Some studies suggest transdermal estrogen (patch, gel, spray) can help regulate blood pressure, while oral estrogen may raise it in some women.

4. Your gut: bacteria that recycle estrogen

Your liver packages used estrogen for removal and sends it to the gut. Certain gut bacteria carry an enzyme called beta-glucuronidase that can unpack it and send it back into circulation. This group of estrogen-handling bacterial genes is called the estrobolome.

The relationship runs both ways. Estrogen shapes the gut microbiome, and the microbiome shapes how much active estrogen you have.

The largest study so far analyzed stool from 2,300 people in the Hispanic Community Health Study/Study of Latinos. Postmenopausal women trended toward lower gut diversity than premenopausal women, and their microbiome looked more like men's. Menopause also reduced the hormone-processing capacity of the gut bacteria. Those changes were linked to worse cardiometabolic risk markers.

This may also connect to a frustrating midlife pattern: losing muscle while gaining fat, called sarcopenic obesity. A 2026 review in the International Journal of Women's Health explains the possible link in three steps:

After menopause, your gut bacteria recycle less estrogen. The enzyme that sends estrogen back into your bloodstream drops off, so you lose one of the few backup sources you had left.
Less estrogen makes it harder to hold on to muscle and easier to store fat, especially around the middle.
A less healthy gut also creates more low-grade inflammation, which wears down muscle and encourages fat storage on its own, separate from estrogen.

Put simply, the gut may be hitting your body composition from two directions at once. This is still a proposed connection, not proven, but it's one more reason gut health belongs in any midlife weight conversation.

Wait, isn't high beta-glucuronidase bad?

If you've read about estrogen dominance, you may have seen beta-glucuronidase described as a problem. Both views can be true, depending on where you are in life.

Before menopause, your ovaries are making plenty of estrogen. Too much gut recycling adds to an already high load, which is the reasoning behind its link to estrogen dominance symptoms. The human research here is thinner than the theory, though.
After menopause, the ovaries have largely stopped. Gut recycling becomes one of the few sources of active estrogen left, and losing it may be part of the problem.
One caution: higher estrogen after menopause is a known breast cancer risk factor. Very high beta-glucuronidase also tends to show up with an unhealthy gut in general.

So the goal isn't a high or low number. It's a balanced, diverse gut that handles estrogen well for your stage of life.

Where the evidence is still thin

The estrobolome is real, but it's early science. Researchers are actively studying its role in breast cancer and endometriosis. One large 2024 study of 1,000 women found no difference in estrobolome genes between women with and without endometriosis. So be cautious of anyone selling a "fix your estrobolome" protocol as settled fact. What the evidence does support is the basics that keep the gut diverse: fiber, a variety of plants, and limiting unnecessary antibiotics.

5. Your liver: why fatty liver rises after menopause

Fatty liver disease, now called MASLD (metabolic dysfunction-associated steatotic liver disease), affects about 1 in 3 adults. In women, it becomes more common and more severe after menopause. One analysis puts the risk at roughly 2.2 times higher after menopause.

A major 2025 review in Endocrine Reviews from the University of Oxford laid out why. The liver is an estrogen-responsive organ. Animal research shows that losing estrogen drives fat buildup in the liver, insulin resistance, and scarring, plus changes in fat tissue and muscle that feed the problem. The authors also pointed out that there are currently no MASLD treatments designed for women, and that the effect of hormone therapy on MASLD is still poorly studied.

Newer data is starting to fill that gap. A large retrospective study using the TriNetX database found that women with existing MASLD who used hormone therapy for perimenopausal symptoms had a lower 5-year risk of serious liver and cardiometabolic outcomes. Oxford is also running a small pilot trial that uses MRI to measure liver fat before and after women start HRT.

The route seems to matter here as well. In a 2023 Korean study, oral hormone therapy was associated with more fatty liver after one year, while transdermal therapy was associated with less. This makes sense: oral estrogen passes through the liver first, and patches and gels don't.

6. Muscle and mitochondria: where energy and blood sugar meet

Muscle cells carry estrogen receptors, and estrogen turns out to be closely tied to the mitochondria, the parts of the cell that make energy.

Researchers at East Carolina University detected estradiol inside the mitochondria of skeletal muscle for the first time. Their work suggests estrogen sits in the mitochondrial membrane and fine-tunes how efficiently it produces energy. In mice, removing the ovaries quickly set up a pre-diabetic state through this mitochondrial pathway, and estrogen replacement reversed it.

A human study of muscle proteins found something similar: estradiol was a major regulator of muscle energy pathways in postmenopausal women. And in animal studies, estrogen replacement improved muscle strength, endurance, and recovery.

This helps explain a pattern many women notice in their late 40s. The same workouts feel harder, recovery takes longer, and weight shifts to the middle even when eating hasn't changed. Muscle is the body's largest site for clearing blood sugar. When its mitochondria work less efficiently, insulin resistance follows.

7. Joints, muscles, and bones: the musculoskeletal syndrome of menopause

If you've started waking up stiff, with achy hands, shoulders, or knees and no injury to explain it, you're far from alone. In 2024, orthopedic surgeon Dr. Vonda Wright and colleagues published a review in Climacteric, the journal of the International Menopause Society, that gave this a name: the musculoskeletal syndrome of menopause.

The numbers are striking. More than 70% of women have musculoskeletal symptoms during the transition from perimenopause to postmenopause, and about 25% are disabled by them. The syndrome pulls together joint pain, muscle loss, frozen shoulder, slower tendon and muscle repair, and bone loss under one cause: falling estrogen. Estrogen receptors are found in cartilage, bone-building cells, tendon, and muscle repair cells, and estrogen itself is anti-inflammatory.

The naming follows the same path as "genitourinary syndrome of menopause," adopted in 2014. A name gets a problem noticed and treated instead of dismissed as aging.

What the trial data shows

The Women's Health Initiative, the study that scared a generation away from hormones, also tested estrogen alone in 10,739 women who'd had a hysterectomy. Women on estrogen reported less joint pain after one year (76.3% vs 79.2% on placebo), and the difference held through year three. Joint swelling was slightly more common on estrogen. The researchers called the pain benefit modest but sustained.

So estrogen doesn't erase joint pain. But it's one tool, alongside strength training and protein, which protect the muscle that holds joints together. For more on what happens to bone in these years, see Bone Loss Starts in Perimenopause.

8. Your immune system: why autoimmunity clusters in women

About 80% of autoimmune diagnoses happen in women, and estrogen is a big part of why. Immune cells, including T cells and B cells, carry estrogen receptors.

A March 2025 study from University College London found that women have a higher proportion of class-switched memory B cells between puberty and menopause than before puberty or after menopause. These cells are highly efficient at fighting infections the body has seen before, which may help explain why women resist some infections better than men. But the same cells can drive more severe symptoms in autoimmune disease.

So estrogen is not simply "good" or "bad" for immunity. It tunes it. Earlier research showed that estrogen receptor alpha on T cells can promote the activation that worsens autoimmune inflammation, while other research tied estrogen loss to T-cell overactivity that drives bone breakdown. That's one reason conditions like rheumatoid arthritis often change course around menopause.

The practical point: new joint, skin, thyroid, or fatigue symptoms in perimenopause deserve a real workup, not an automatic "it's just hormones." Sometimes it's both.

9. Bladder and urinary tract: vaginal estrogen may protect more than comfort

Estrogen keeps the tissue of the vagina, urethra, and bladder thick and healthy. It also helps vaginal cells make glycogen, which feeds the protective Lactobacillus bacteria. When estrogen drops, the local pH rises, the good bacteria fade, and urinary tract infections become more common.

Vaginal estrogen has been shown to reduce recurrent UTIs since the 1990s. A meta-analysis found about a 60% lower risk.

What's new is the size of the outcome data. A 2025 analysis of the Epic Cosmos health records database looked at nearly 1.9 million women with recurrent UTIs. Women prescribed vaginal estrogen within two months of their second infection had lower rates of sepsis, hospitalization, and death, across every age group studied. This was an observational study, so it shows an association rather than proof. But for a treatment this simple, it's a strong reason to ask about it.

Local vaginal estrogen barely raises estrogen levels in the bloodstream, which is why it's considered low-risk even for many women who can't use systemic hormones.

10. What changed in the official guidance

For 22 years, every estrogen product in the U.S. carried a black box warning, the FDA's strongest, about heart disease, breast cancer, and dementia. It came from the 2002 Women's Health Initiative results, which studied one oral hormone combination in women who were, on average, in their 60s. Those warnings were then applied to every dose, route, and form, including low-dose vaginal creams.

On November 10, 2025, HHS and the FDA announced they would remove the boxed warning language on cardiovascular disease, breast cancer, and probable dementia. Here's what changed:

The dementia warning was removed from labeling entirely.
Heart disease and breast cancer information stays on the label, but outside the black box.
The boxed warning on endometrial cancer stays for estrogen-only products in women with a uterus. That's why progesterone matters if you still have your uterus.
The old "lowest dose for the shortest time" mandate was dropped.
Labels now include guidance on starting within 10 years of menopause or before age 60.

The first six updated labels were approved after 29 manufacturers submitted revisions, and more are rolling out.

Not everyone agrees with the change. Some critics argue it was driven by opinion rather than new safety data. Hormone therapy still has real risks that depend on your age, health history, and the type and route you use. What has changed is that the conversation can now start from accurate information instead of fear.

What this means for you

Put the research together and a clear picture comes out. Perimenopause isn't a reproductive event with a few side effects. It's a whole-body transition, and the symptoms that seem unrelated often share one root.

A few practical takeaways:

Don't wait for menopause to take this seriously. The brain receptor changes start in perimenopause, and the heart data favors acting early.
Track symptoms across systems. Brain fog, night sweats, joint pain, new belly fat, recurrent UTIs, and changes in digestion can all trace back to the same hormonal shift.
Frequent night sweats are worth a closer look at blood pressure, lipids, blood sugar, and sleep.
Route matters. Transdermal and oral estrogen don't behave the same way in the liver or blood vessels.
Vaginal estrogen is a separate, low-risk conversation from systemic hormone therapy, and worth having if UTIs or dryness are an issue.
The foundations still do heavy lifting. Strength training, adequate protein, fiber, and sleep support muscle, gut, liver, and joints whether or not you use hormones.

Every woman's risks and options are different, and hormone therapy isn't right for everyone. The goal is a plan built on your history, your labs, and your symptoms.

References

Mosconi L, Nerattini M, Matthews DC, et al. In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology. Sci Rep. 2024;14:12680. View source
Itoh N, Itoh Y, Meyer CE, et al. Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice. Nat Commun. 2023;14:6044. View source
Itoh N, Voskuhl R, et al. Targeting hormone treatment for the brain in menopause. Sci Rep. Published online September 1, 2026. UCLA Health news release. View source
Thurston RC, Aizenstein HJ, Derby CA, Sejdić E, Maki PM. Menopausal hot flashes and white matter hyperintensities. Menopause. 2016. View source
Thurston RC, et al. Vasomotor symptoms and white matter hyperintensities. Neurology. January 2023. Summary in Today's Geriatric Medicine. View source
Layton A, et al. Estrogen and blood pressure regulation model. Mathematical Biosciences. Summary in Medical News Today. View source
Hodis HN, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016. NPR summary. View source
Peters BA, Lin J, Qi Q, et al. Menopause is associated with an altered gut microbiome and estrobolome, with implications for adverse cardiometabolic risk in the Hispanic Community Health Study/Study of Latinos. mSystems. 2022;7(3):e0027322. View source
Gut microbiota has the potential to improve sarcopenic obesity in menopausal women by regulating estrogen. Int J Womens Health. Vol. 18, 2026. View source
Gut microbiome in endometriosis: a cohort study on 1000 individuals. BMC Med. 2024;22(1):294. View source
Dong J, Dennis KMJH, Venkatakrishnan R, Hodson L, Tomlinson JW. The impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy. Endocr Rev. 2025;46:790–809. View source
Effect of hormone replacement therapy on liver and cardiometabolic outcomes in peri-menopausal MASLD. View source
Menopause and increased risk of MASLD (FPIN Clinical Inquiry). Am Fam Physician. July 2026. View source
Torres MJ. Unravelling the mechanisms of menopause-induced insulin resistance: novel roles for estradiol in skeletal muscle mitochondrial function. East Carolina University. View source
Estrogen regulates muscle bioenergetic signaling. Aging. 2018. View source
Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466–472. View source
Chlebowski RT, Cirillo DJ, Eaton CB, et al. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause. 2013. View source
University College London. Abundance of key immune cells may be influenced by oestrogen and XX chromosomes. March 25, 2025. View source
Mohammad I, et al. Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation. Sci Signal. 2018. View source
LaClair J, Visingardi J, Wells B, Feustel P, Deckert J, De EJB. Vaginal estrogen prescription is associated with reduced risk of serious adverse outcomes in women of all age groups with recurrent urinary tract infection: an Epic Cosmos database analysis. Summary in Medical Dialogues. View source
FDA initiates removal of boxed warnings, requests updated labeling for menopausal hormone therapy. Contemporary OB/GYN. November 10, 2025. View source
Elimination of the black box warning on menopausal hormone therapy. Obstet Gynecol. 2026;147(5):642–646. View source